( MENAFN - GlobeNewsWire - Nasdaq) ELAN Investors with Losses Encouraged to Contact the Firm SAN FRANCISCO, Oct. 28, 2024 (GLOBE NEWSWIRE) -- A federal lawsuit has been filed in the U.S.
District Court of Maryland against Elanco Animal health Inc. and specific executives, accusing them of making false and misleading statements between November 7, 2023, and June 26, 2024. Hagens Berman urges Elanco Animal Health Incorporated (NYSE: ELAN) investors who suffered substantial losses to submit your losses now .
Class Period: Nov. 7, 2023 – June 26, 2024 Lead Plaintiff Deadline: Dec. 6, 2024 Visit: Contact the Firm Now: .
.. 844-916-0895 Class Action Lawsuit Against Elanco Animal Health Incorporated (ELAN): The complaint alleges that the company minimized potential safety risks associated with Zenrelia, an oral Janus kinase inhibitor, while exaggerating its prospects for a swift U.
S. market launch. The controversy erupted on June 26, 2024, when Elanco revealed that Zenrelia's label would include a boxed warning, highlighting safety issues identified during trials with unvaccinated dogs.
The warning is anticipated to significantly hinder product adoption and limit treatment days. Following the disclosure, Elanco's stock plummeted by over 20%. During the company's Q2 earnings call on August 4, 2024, CEO Jeffrey N.
Simmons conceded that the label language would "slow the initial product adoption curve" due to the necessity for targeted veterinary education. Simmons also projected a 25.